AbCellera Biologics Inc.
ABCL Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$11.82
KIRA · Stoqly’s AI analyst, in plain words
- AbCellera Biologics Inc. had $75.1M of revenue in fiscal 2025, up 160.6% on the year before. Over five years, revenue changed −20.3% a year on average.
- Its operating margin was −289.0%, up 802.7 pts: of every 100 in sales, about −289 is left after running the business.
- AbCellera Biologics Inc. lost $146M in fiscal 2025.
- Free cash flow was −$174M in fiscal 2025, −231.7% of revenue.
Market cap
$3.6B
P/E
—
Revenue
$75.1M
Net income
−$146M
Free cash flow
−$174M
Operating margin
−289.0%
AbCellera Biologics Inc. in 30 seconds · fiscal 2025
Are sales growing?
+160.6%
Yes. Sales grew 160.6% last year.
Does it make a profit?
−194.9%
No. It lost money last year.
Does profit turn into cash?
−231.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What AbCellera Biologics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- AbCellera Biologics Inc.
- CIK
- 0001703057
AbCellera Biologics Inc. · ABCL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $375M | $485M | $38.0M | $28.8M | $75.1M |
| Revenue growth | 60.9% | 29.4% | −92.2% | −24.2% | 160.6% |
| Operating margin | 54.5% | 44.6% | −623.8% | −1,091.7% | −289.0% |
| Net income | $153M | $159M | −$146M | −$163M | −$146M |
| Net margin | 40.9% | 32.7% | −385.0% | −564.8% | −194.9% |
| Diluted EPS | $0.48 | $0.50 | −$0.51 | −$0.55 | −$0.49 |
| Cash | |||||
| Cash from operations | $245M | $277M | −$43.9M | −$109M | −$131M |
| Capital expenditure | $58.5M | $70.7M | $76.9M | $78.4M | $42.8M |
| Free cash flow | $186M | $207M | −$121M | −$187M | −$174M |
| FCF margin | 49.6% | 42.6% | −317.7% | −648.4% | −231.7% |
| Share count change | 21.0% | −1.1% | −8.2% | 1.8% | 1.5% |
| Debt and strength | |||||
| Cash and short-term investments | $476M | $387M | $133M | $156M | $129M |
| Shareholders' equity | $1.0B | $1.2B | $1.2B | $1.1B | $967M |
| Current ratio | 7.7x | 8.7x | 7.3x | 9.8x | 11.3x |
| Returns and quality | |||||
| Return on equity | 16.5% | 14.0% | −12.3% | −14.7% | −14.5% |
| Return on tangible equity | 18.5% | 15.0% | −14.9% | −16.9% | −16.6% |
| Piotroski F-score | 4 | 6 | 2 | 2 | 4 |
| Altman Z'' | 9.4 | 9.9 | 6.5 | 5.6 | 4.7 |
Insiders bought, 12 months
$2.7M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
AbCellera Biologics Inc. · ABCL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $11.82 a share, the company is worth $3.6B.
Source: SEC EDGAR XBRL filings (CIK 0001703057). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.